SBIR-STTR Award

Robust; Defined; Animal-Free Cell Culture Medium For The Production Of Vaccines
Award last edited on: 7/26/13

Sponsored Program
SBIR
Awarding Agency
NIH : NIAID
Total Award Amount
$1,675,691
Award Phase
2
Solicitation Topic Code
-----

Principal Investigator
Steve Clyde Pettit

Company Information

Ventria Bioscience (AKA: Applied Phytologics Inc)

12635 East Montview Boulevard
Aurora, CO 80045
   (800) 916-8311
   info@ventria.com
   www.ventria.com
Location: Single
Congr. District: 06
County: Adams

Phase I

Contract Number: 1R43AI092916-01A1
Start Date: 7/8/11    Completed: 2/29/12
Phase I year
2011
Phase I Amount
$158,820
Epithelial cell lines such as Vero and MDCK are used in the production of viral based vaccines. The use of cell based vaccines is growing. The majority of the vaccines in use today are produced in medium supplemented with serum. The use of animal-derived products in vaccine culture media presents a risk for the transmission of infectious disease on a wide scale. Current commercially available serum-free vaccine media, are not defined, inconsistent, and do not offer the same performance as media supplemented with serum. We propose to produce a superior performance, defined, animal-free, cell culture medium for vaccine production. Our project addresses the call by agencies for a safe alternative to animal-derived components in vaccine production.

Public Health Relevance:
Epithelial cell lines such as Vero and MDCK are used in the generation of viral based vaccines and their use is expanding. Current commercially available animal-free vaccine production media are not defined and do not offer the same performance as media supplemented with serum. We propose the industry's first defined, high performance animal-free, cell culture medium to increase safety and the production of vaccines.

Thesaurus Terms:
0-11 Years Old;2-Aminoethanol;21+ Years Old;Abscission;Address;Adult;Adult Human;Amino Acids;Aminoethanols;Animals;Biological;Biometals;Blood Plasma;Blood Serum;Cell Culture Techniques;Cell Line;Cellline;Cells;Cellular Expansion;Cellular Growth;Child;Child Human;Child Youth;Children (0-21);Colamine;Culture Media;Development;Disadvantaged;Drug Formulations;Epithelial;Epithelial Cells;Ethanolamines;Excision;Extirpation;Fda Approved;Feasibility Studies;Flu Vaccine;Formulation;Foundations;Gfac;General Viruses;Generalized Growth;Generations;Granulocyte/Pollen-Binding Protein;Growth;Growth Agents;Growth Factor;Growth Substances;History;Human;Industry;Infectious Agent;Influenza Vaccines;Influenza Virus Vaccine;Kidney;Kidney Urinary System;Loinc Axis 2 Property;Loinc Axis 4 System;Mdck Cell;Madin Darby Canine Kidney Cell;Man (Taxonomy);Marketing;Methods;Modern Man;Monoethanolamine;Oncogenic;Performance;Phase;Plants;Plasma;Plasma Albumin;Plasma Serum;Population;Prp Proteins;Prion Proteins;Prions;Production;Productivity;Property;Proteins;Proteins Growth Factors;Recombinants;Recording Of Previous Events;Removal;Reticuloendothelial System, Serum, Plasma;Rice;Risk;Safety;Serum;Serum Albumin;Serum Proteins;Siderophilin;Solutions;Source;Strains Cell Lines;Surgical Removal;Suspension Substance;Suspensions;System;Testing;Time;Tissue Growth;Trace Elements;Trace Mineral;Transferrin;Update;Vaccine Production;Vaccines;Vero Cells;Viral;Viral Vaccines;Virus;Vitamins;World Health Organization;Adult Human (21+);Adulthood;Aminoacid;Base;Cell Culture;Cell Growth;Children;Communicable Disease Transmission;Continuous Cell Line;Cost;Cost Effective;Cost-Effective;Cultured Cell Line;Density;Developmental;Disease Transmission;Egg;Gene Product;Growth Media;Improved;Infectious Disease Transmission;Infectious Organism;Novel;Ontogeny;Renal;Resection;Suspension;Vaccine Safety;Youngster

Phase II

Contract Number: 2R44AI092916-02
Start Date: 00/00/00    Completed: 00/00/00
Phase II year
2012
(last award dollars: 2013)
Phase II Amount
$1,516,871

The Vero cell line is used in the production of viral based vaccines. The use of cell based vaccines based on the Vero cell line is growing. The majority of the vaccines in use today are produced using cell culture medium supplemented with serum. The use of animal-derived products in vaccine culture media presents a risk for the transmission of infectious disease on a wide scale. Current commercially available serum-free vaccine media are not defined, inconsistent, and do not offer the same performance as media supplemented with serum. We propose to produce a superior performance, defined, animal-free, cell culture medium for vaccine production. Our project addresses the call by agencies for a safe alternative to animal-derived components in vaccine production.

Public Health Relevance:
Epithelial cell lines such as Vero are used in the manufacture of viral based vaccines and their use is expanding. Current commercially available animal-free vaccine production media are not defined and do not offer the same performance as media supplemented with serum. We propose the industry's first defined, high performance animal-free, cell culture medium to increase the safety and the production of vaccines.